C. Geroldi
6 Papers
165 Citations
C. Geroldi is an academic researcher. The author has contributed to research in topics: Dementia & Insulin resistance. The author has an hindex of 4, co-authored 6 publications.
Chat about Author
Papers
•Journal Article
Apolipoprotein E&4 allele in Alzheimer's disease and vascular dementia
Giovanni B. Frisoni,Laura Calabresi,C. Geroldi,Angelo Bianchetti,A. L. D'acquarica,S. Govoni,Cesare R. Sirtori,M. Trabucchi,G. Franceschini +8 more
TL;DR: The frequency of the E4 allele of the apolipoprotein E (apoE) is increased in familial and sporadic late-onset Alzheimer's disease, but its prevalence in non-Alzheimer dementias in Caucasian popu
116
Reality Orientation Therapy to delay outcomes of progression in patients with dementia. A retrospective study
Tiziana Metitieri,Orazio Zanetti,C. Geroldi,Giovanni B. Frisoni,Diego De Leo,Marirosa Dello Buono,Angelo Bianchetti,M. Trabucchi +7 more
TL;DR: Conclusions: Continued ROT classes during the early to middle stages of dementia may delay nursing home placement and slow down the progression of cognitive decline.
49
•Journal Article
Insulin resistance in cognitive impairment: the InCHIANTI study
C. Geroldi,Giovanni B. Frisoni,Giuseppe Paolisso,Stefania Bandinelli,M. Lamponi,Angela Marie Abbatecola,Orazio Zanetti,Jack M. Guralnik,Luigi Ferrucci +8 more
TL;DR: In this paper, the association between cognitive impairment, with and without subcortical features, and insulin resistance in an elderly community-dwelling population was tested. But the results were limited to individuals who had experienced stroke.
2
Insulin resistance in cognitive impairment: the InCHIANTI study.
C. Geroldi,Giovanni B. Frisoni,Giuseppe Paolisso,Stefania Bandinelli,M. Lamponi,Angela Marie Abbatecola,Orazio Zanetti,Jack M. Guralnik,Luigi Ferrucci +8 more
TL;DR: Cognitive impairment with but not without subcortical features is associated with biochemical and clinical features of insulin resistance syndrome and in epidemiologic populations, insulin resistance might contribute to cognitive impairment through a vascular mechanism.
Drug treatment in Lewy body dementia.
TL;DR: Treatment strategies and outcomes of 10 clinically diagnosed LBD patients were described, with 6 patients taking L-dopa or antiparkinsonian drugs and 6 having a moderate or good response with no or only mild adverse effects.